Table 7.
Clinical consequences and medicines of reported medication errors
| Country | Type of error | Medicines | Clinical consequences | Reference |
|---|---|---|---|---|
| Israel | Prescribing | Anti-infectives, TPN, cytotoxics | Errors divided into potentially serious, clinically significant and clinically non-significant. MEs most frequent in haemato-oncology and these were the errors that were of greatest clinical significance | [14] |
| Saudi Arabia | Prescribing | Not stated | Examples of potentially serious errors were given including tenfold errors of amphotericin and captopril | [26] |
| Israel | Prescribing | Cardiovascular drugs | 14 MEs (8 %) were clinically significant. There were also 3 (2 %) severe MEs | [30] |
| Saudi Arabia | Prescribing | IV fluids, antibiotics, bronchodilators, opioid analgesics, cardiovascular drugs, sedatives | Majority of MEs were potentially harmful (1051, 79 %) | [21] |
| Saudi Arabia | Prescribing | Antibiotics, cardiovascular drugs | MEs were a contributory factor to 26 deaths | [31] |
| Iran | Administration | Antibiotics, antacids, corticosteroids | No clinically significant errors detected | [38] |